Current Psychiatry Reports

, Volume 8, Issue 3, pp 234–240 | Cite as

Treatment of depression in Parkinson’s disease

  • Matthew Menza
  • Roseanne DeFronzo Dobkin
  • Humberto Marin

Abstract

Depression is one of the most common nonmotor features observed in Parkinson’s disease (PD), affecting approximately 40% of patients. Depression in Parkinson’s disease (dPD) significantly affects quality of life of both patients and their families and has been shown to be more predictive of distress than motor disability. Depression frequently goes unrecognized in this population, however, in part because the diagnosis is often complicated by the overlap of psychiatric and PD symptoms. The etiology of dPD is unclear; dopaminergic, serotonergic, and noradrenergic systems may be implicated. Options for managing dPD include antidepressant medication; cognitive-behavioral therapy; behavioral lifestyle interventions such as exercise; and, in refractory cases, noninvasive brain stimulation (electroconvulsive therapy, transcranial magnetic stimulation). Randomized controlled trials are needed to evaluate the efficacy of interventional approaches for dPD; several trials are currently underway.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Martilla RJ: Epidemiology. In Handbook of Parkinson’s Disease, edn 2. Edited by Koller WC. New York: Marcel Dekker; 1992:35–57.Google Scholar
  2. 2.
    Bower JH, Maraganore DM, McDonnell SK, et al.: Incidence and distribution of parkinsonism in Olmsted County, Minnesota. Neurology 1999, 52:1214–1220.PubMedGoogle Scholar
  3. 3.
    Global Parkinson’s Disease Steering Committee: Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 2002, 17:60–67.CrossRefGoogle Scholar
  4. 4.
    Shulman LM, Taback RL, Rabinstein AA, Weiner WJ: Nonrecognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 2002, 8:193–197. Informative study describing nonrecognition of depression in PD.PubMedCrossRefGoogle Scholar
  5. 5.
    Cummings JL: Depression and Parkinson’s disease. Am J Psychiatry 1992, 149:443–454. Excellent review article.PubMedGoogle Scholar
  6. 6.
    Papapetropoulos S, Ellul J, Argyriou A A, et al.: The effect of depression on motor function and disease severity of Parkinson’s disease. Clin Neurol Neurosurg 2005 [Epub ahead of print].Google Scholar
  7. 7.
    Starkstein SE, Mayberg HS, Leiguarda R, et al.: A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1992, 55:377–382.PubMedGoogle Scholar
  8. 8.
    Starkstein SE, Preziosi TJ, Bolduc PL, et al.: Depression in Parkinson’s disease. J Nerv Ment Dis 1990, 178:27–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Brown RG, MacCarthy B, Gotham AM, et al.: Depression and disability in Parkinson’s disease: a follow-up of 132 cases. Psychol Med 1988, 18:49–55.PubMedCrossRefGoogle Scholar
  10. 10.
    Holroyd HS, Currie LJ, Wooten GF: Depression is associated with impairment of ADL, not motor function in Parkinson’s disease. Neurology 2005, 64:2134–2135.PubMedCrossRefGoogle Scholar
  11. 11.
    Grosset KA, Bone I, Grosset DG: Suboptimal medication adherence in Parkinson’s disease. Mov Disord 2005, 20:1502–1507.PubMedCrossRefGoogle Scholar
  12. 12.
    Schrag A, Jahanshahi M, Quinn N: What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 2000, 69:308–312.PubMedCrossRefGoogle Scholar
  13. 13.
    Whetten-Goldstein K, Sloan F, Kulas E, et al.: The burden of Parkinson’s disease on society, family, and the individual. J Am Geriatr Soc 1997, 45:844–849.PubMedGoogle Scholar
  14. 14.
    Marsh L, McDonald WM, Cummings J, et al.: Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord 2005, 21:148–158. Excellent review of diagnostic issues in depression and PD, from a conference sponsored by the National Institute of Mental Health.CrossRefGoogle Scholar
  15. 15.
    Richard IH, Justus AW, Kurlan R: Relationship between mood and motor fluctuations in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2001, 13:35–41.PubMedGoogle Scholar
  16. 16.
    Hardie RT, Lees AJ, Stern GM: On-off fluctuations in Parkinson’s disease. Brain 1984, 107:487–506.PubMedCrossRefGoogle Scholar
  17. 17.
    Cantello R, Gilli M, Riccio A, et al.: Mood changes associated with end-of-dose deterioration in Parkinson’s disease: a controlled study. J Neurol Neurosurg Psychiatry 1986, 49:1182–1190.PubMedGoogle Scholar
  18. 18.
    Stenager EN, Wermuth L, Stenager E, Boldsen J: Suicide in patients with Parkinson’s disease. An epidemiological study. Acta Psychiatr Scand 1994, 90:70–72.PubMedGoogle Scholar
  19. 19.
    Myslobodsky M, Lalonde FM, Hicks L: Are patients with Parkinson’s disease suicidal? J Geriatr Psychiatry Neurol 2001, 14:120–124. Good article on suicide in PD.PubMedCrossRefGoogle Scholar
  20. 20.
    Menza MA: The personality associated with Parkinson’s disease [review]. Curr Psychiatry Rep 2000, 2:421–426. Good background article.PubMedCrossRefGoogle Scholar
  21. 21.
    Aarsland D, Larsen JP, Cummings JL, Laake K: Prevalence and clinical correlates of psychotic symptoms in Parkinson’s disease: a community-based study. Arch Neurol 1999, 56:595–601.PubMedCrossRefGoogle Scholar
  22. 22.
    Marsh L, Williams JR, Rocco M, et al.: Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004, 63:293–300.PubMedGoogle Scholar
  23. 23.
    Menza MA, Robertson-Hoffmann DE, Bonapace AS: Parkinson’s disease and anxiety: comorbidity with depression. Biol Psychiatry 1993, 34:465–470.PubMedCrossRefGoogle Scholar
  24. 24.
    Henderson R, Kurlan R, Kersun JM, Como P: Preliminary examination of the comorbidity of anxiety and depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992, 4:257–264.PubMedGoogle Scholar
  25. 25.
    Schiffer RB, Kurlan R, Rubin A, et al.: Evidence of atypical depression in Parkinson’s disease. Am J Psychiatry 1988, 145:1020–1022.PubMedGoogle Scholar
  26. 26.
    Chrischilles EA, Rubenstein LM, Voelker MD, et al.: Linking clinical variables to health-related quality of life in Parkinson’s disease. Parkinsonism Relat Disord 2002, 8:199–209.PubMedCrossRefGoogle Scholar
  27. 27.
    Shulman LM, Taback RL, Bean J, Weiner WJ: Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Disord 2002, 16:507–510.CrossRefGoogle Scholar
  28. 28.
    Tandberg E, Larsen JP, Aarsland D, et al.: Risk factors for depression in Parkinson’s disease. Arch Neurol 1997, 54:625–630. A good review of risk factors for depression in PD.PubMedGoogle Scholar
  29. 29.
    Menza MA: Parkinson’s disease and depression: the relationship to personality and disability. J Neuropsychiatry Clin Neurosci 1994, 6:165–169.PubMedGoogle Scholar
  30. 30.
    Ehmann TS, Beninger RJ, Gawel MJ, Riopelle RJ: Depressive symptoms in Parkinson’s disease: a comparison with disabled control subjects. J Geriatr Psychiatry Neurol 1990, 3:3–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Shiba M, Bower JH, Maraganore DM, et al.: Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord 2000, 15:669–677. Interesting article suggesting that anxiety and depression may predispose to PD.PubMedCrossRefGoogle Scholar
  32. 32.
    Fukkunishi I, Hosokawa K, Ozaki S: Depression antedating the onset of Parkinson’s disease. Jpn J Psychiatry Neurol 1991, 45:7–11.Google Scholar
  33. 33.
    Mayberg H, Solomon D: Depression in Parkinson’s disease: a biochemical and organic viewpoint. In Behavioral Neurology of Movement Disorders. Edited by Weiner WJ, Lang AE. New York: Raven Press; 1995:49–60.Google Scholar
  34. 34.
    Jellinger KA: Morphological substrates of mental dysfunction in Lewy body disease: an update. J Neural Transm Suppl 2000, 59:185–212.PubMedGoogle Scholar
  35. 35.
    Mayeux R: Depression in the patient with Parkinson’s disease [review]. J Clin Psychiatry 1990, 51(Suppl 20–3):20–23.PubMedGoogle Scholar
  36. 36.
    Cantello R, Aguaggia M, Gilli M, et al.: Major depression in Parkinson’s disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse. J Neurol Neurosurg Psychiatry 1989, 52:724–731.PubMedGoogle Scholar
  37. 37.
    Mayberg HS: Limbic-cortical dysregulation: a proposed model of depression [review]. J Neuropsychiatry Clin Neurosci 1997, 9:471–481. Excellent review of proposed mechanisms of depression in PD.PubMedGoogle Scholar
  38. 38.
    Torack RM, Morris JC: The association of ventral tegmental area histopathology with adult dementia. Arch Neurol 1988, 45:497–501.PubMedGoogle Scholar
  39. 39.
    Weintraub D, Newberg AB, Cary MS, et al.: Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med 2005, 46:227–232.PubMedGoogle Scholar
  40. 40.
    Kostic VS, Djuricic BM, Covickovic-Sternic N, et al.: Depression and Parkinson’s disease: possible role of serotonergic mechanisms. J Neurol 1987, 234:94–96.PubMedCrossRefGoogle Scholar
  41. 41.
    Kish SJ: Biochemistry of Parkinson’s disease: Is a brain serotonergic deficiency a characteristic of idiopathic Parkinson’s disease? In Parkinson’s Disease (Advances in Neurology, Vol. 91). Edited by Gordin A, Kaakkola S, Teravainen H. Philadelphia: Lippincott Williams & Wilkins; 2003:39–49.Google Scholar
  42. 42.
    Remy P, Doder M, Lees A, et al.: Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128:1314–1322.PubMedCrossRefGoogle Scholar
  43. 43.
    Nagatsu T, Sawada M: Infiammatory process in Parkinson’s disease: role for cytokines [review]. Curr Pharm Des 2005, 11:999–1016.PubMedCrossRefGoogle Scholar
  44. 44.
    Strang RR: Imipramine in treatment of parkinsonism: a double blind placebo study. Br Med J 1965, 2:33–34.PubMedCrossRefGoogle Scholar
  45. 45.
    Anderson J, Aabro E, Gulmann AE, et al.: Anti-depressive treatment in Parkinson’s disease: a controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-dopa. Acta Neurol Scand 1980, 62:210–219.CrossRefGoogle Scholar
  46. 46.
    Laitinen L: Desipramine in treatment of Parkinson’s disease. Acta Neurol Scand 1969, 45:109–113.PubMedCrossRefGoogle Scholar
  47. 47.
    Goetz CG, Tanner CM, Klawans HL: Bupropion in Parkinson’s disease. Neurology 1984, 34:1092–1094.PubMedGoogle Scholar
  48. 48.
    Hauser RA, Zesiewicz TA: Sertraline for the treatment of depression in Parkinson’s disease. Mov Disord 1997, 12:756–759.PubMedCrossRefGoogle Scholar
  49. 49.
    Meara J, Hobson P: Sertraline for the treatment of depression in Parkinson’s disease [letter]. Mov Disord 1998, 13:622.PubMedCrossRefGoogle Scholar
  50. 50.
    Ceravolo R, Nuti A, Piccinni A, et al.: Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology 2000, 55:1216–1218.PubMedGoogle Scholar
  51. 51.
    Tesei S, Antonini A, Canesi M, et al.: Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov Disord 2000, 15:986–989.PubMedCrossRefGoogle Scholar
  52. 52.
    Dell’Agnello G, Cervolo R, Nuti A, et al.: SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharm 2001, 24:221–227.CrossRefGoogle Scholar
  53. 53.
    Pintor L, Bailles E, Valldeoriola F, et al.: Response to 4-month treatment with reboxetine in Parkinson’s disease patients with a major depressive episode. Gen Hosp Psychiatry 2005, 28:59–64.CrossRefGoogle Scholar
  54. 54.
    Wermuth L, Sorensen PS, Timm S, et al.: Depression in idiopathic Parkinson’s disease treated with paroxetine. A placebo-controlled trial. Nord J Psychiatry 1998, 52:163–169.CrossRefGoogle Scholar
  55. 55.
    Serrano Dueñas M: A comparison between low doses of amitriptyline and low doses of fluoxetine used in the control of depression in patients suffering from Parkinson’s disease [in Spanish]. Rev Neurol 2002, 35:1010–1014.PubMedGoogle Scholar
  56. 56.
    Weintraub D, Morales KH, Moberg PJ, et al.: Antidepressant studies in Parkinson’s disease: a review and meta-analysis [review]. Mov Disord 2005, 20:1161–1169. A good review of studies of antidepressants in depression and PD.PubMedCrossRefGoogle Scholar
  57. 57.
    Richard IH, Kurlan R: A survey of antidepressant drug use in Parkinson’s disease. Neurology 1997, 49:1168–1170.PubMedGoogle Scholar
  58. 58.
    Takahashi H, Kamata M, Yoshida K, et al.: Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson’s disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:351–353.PubMedCrossRefGoogle Scholar
  59. 59.
    Corrigan MH, Denahan AQ, Wright CE, et al.: Comparison of pramipexole, fluoxetine and placebo in patients with major depressive disorder. Depress Anx 2000, 11:58–65.CrossRefGoogle Scholar
  60. 60.
    Rektorova I, Rektor I, Bares M, et al.: Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol 2003, 10:399–406. A good controlled study.PubMedCrossRefGoogle Scholar
  61. 61.
    Gerber PE, Lynd LD: Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998, 32:692–698.PubMedCrossRefGoogle Scholar
  62. 62.
    Zesiewicz TA, Gold M, Chari G, Hauser RA: Current issues in depression in Parkinson’s disease. Am J Geriatr Psychiatry 1999, 7:110–118.PubMedGoogle Scholar
  63. 63.
    Gony M, Lapeyre-Mestre M, Montastruc JL, French Network of Regional Pharmacovigilance Centers: Risk of serious extrapyramidal symptoms in patients with Parkinson’s disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs [review]. Clin Neuropharmacol 2003, 26:142–145.PubMedCrossRefGoogle Scholar
  64. 64.
    Elsworth JD, Glover V, Reynolds GP, et al.: Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the "cheese effect". Psychopharmacology 1978, 57:33–38.PubMedCrossRefGoogle Scholar
  65. 65.
    Jermain DM, Hughes PL, Follender AB: Potential fluoxetine-selegiline interaction [letter]. Ann Pharmacother 1992, 26:1300.PubMedGoogle Scholar
  66. 66.
    Shabnam GN, Chung TH, Deane KHO, et al.: Therapies for depression in Parkinson’s disease. Cochrane Database Syst Rev 2003, 3:CD003465.PubMedGoogle Scholar
  67. 67.
    DeFronzo-Dobkin R, Allen LA, Menza M: Cognitive-behavioral treatment package for depression in Parkinson’s disease. Psychosomatics 2006, In press.Google Scholar
  68. 68.
    Dreising H, Beckmann J, Wermuth L, et al.: Psychologic effects of structured cognitive psychotherapy in young patients with Parkinson’s disease: a pilot study. Nordic J Psychiatry 1999, 53:217–221.CrossRefGoogle Scholar
  69. 69.
    Battile J, Langbein WE, Weaver F, et al.: Effect of exercise on perceived quality of life of individuals with Parkinson’s disease. J Rehabil Res Dev 2000, 37:529–534.Google Scholar
  70. 70.
    Ouchi Y, Yoshikawa E, Futatsubachi M, et al.: Effect of simple motor performance on regional dopamine release in the striatum in Parkinson’s disease patients and healthy subjects: a positron emission tomography study. J Cereb Blood Flow Metab 2002, 22:746–752.PubMedCrossRefGoogle Scholar
  71. 71.
    Kalteis K, Standhardt H, Kryspin-Exner I, et al.: Infiuence of bilateral Stn-stimulation on psychiatric symptoms and psychosocial functioning in patients with Parkinson’s disease. J Neural Transm 2005 [Epub ahead of print].Google Scholar
  72. 72.
    Funkiewiez A, Ardouin C, Caputo E, et al.: Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004, 75:834–839.PubMedCrossRefGoogle Scholar
  73. 73.
    Piasecki S, Jefferson JW: Psychiatric complications of deep brain stimulation for Parkinson’s disease. J Clin Psychiatry 2004, 65:845–849.PubMedCrossRefGoogle Scholar
  74. 74.
    Duyon R, Serby M, Klutchko B, Rotrosen J: ECT and Parkinson’s disease revisited: a "naturalistic" study. Am J Psychiatry 1989, 146:1451–1455.Google Scholar
  75. 75.
    Fregni F, Santos CM, Myczkowski ML, et al.: Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004, 75:1171–1174.PubMedCrossRefGoogle Scholar
  76. 76.
    Dragasevic N, Potrebic A, Damjanovic A, et al.: Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson’s disease: an open study. Mov Disord 2002, 17:528–532.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2006

Authors and Affiliations

  • Matthew Menza
    • 1
  • Roseanne DeFronzo Dobkin
  • Humberto Marin
  1. 1.Department of PsychiatryRobert Wood Johnson Medical SchoolPiscatawayUSA

Personalised recommendations